Shares of Vir Biotechnology Inc. VIR, -3.02% were up 1.0% in trading on Thursday after the company and GlaxoSmithKline GSK, +0.02% formally asked the Food and Drug Administration to update the authorization for their COVID-19 treatment to include intramuscular administration. GSK’s stock was up 0.1% after the news was announced. The therapy, sotrovimab, is a monoclonal antibody used to treat some teens and adults who are at high risk for severe COVID-19. The therapy was originally authorized for single-dose intravenous infusion. Vir’s stock is down 3.8% and GSK shares have gained 2.7% so far this year. The S&P 500 SPX, -0.04% has declined 0.8%.